Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Expands By 11.7%

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 2,010,000 shares, a growth of 11.7% from the February 29th total of 1,800,000 shares. Approximately 7.1% of the shares of the company are short sold. Based on an average trading volume of 256,400 shares, the short-interest ratio is presently 7.8 days.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ITOS. PNC Financial Services Group Inc. lifted its position in shares of iTeos Therapeutics by 131.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,287 shares of the company's stock worth $25,000 after acquiring an additional 1,299 shares during the period. Tower Research Capital LLC TRC boosted its stake in iTeos Therapeutics by 168.3% during the third quarter. Tower Research Capital LLC TRC now owns 2,648 shares of the company's stock worth $29,000 after buying an additional 1,661 shares in the last quarter. Federated Hermes Inc. increased its holdings in iTeos Therapeutics by 4,648.4% in the 4th quarter. Federated Hermes Inc. now owns 2,944 shares of the company's stock valued at $32,000 after buying an additional 2,882 shares during the period. Gladius Capital Management LP raised its stake in shares of iTeos Therapeutics by 48.7% in the 4th quarter. Gladius Capital Management LP now owns 3,131 shares of the company's stock valued at $34,000 after buying an additional 1,026 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in shares of iTeos Therapeutics by 94.3% in the 2nd quarter. Royal Bank of Canada now owns 2,586 shares of the company's stock valued at $34,000 after buying an additional 1,255 shares in the last quarter. 97.16% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ITOS has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $44.00 price target on shares of iTeos Therapeutics in a research report on Thursday, March 7th. Wedbush restated an "outperform" rating and set a $18.00 price target (down from $25.00) on shares of iTeos Therapeutics in a report on Wednesday, March 6th.

iTeos Therapeutics Stock Performance

Shares of ITOS traded down $0.30 during mid-day trading on Monday, hitting $13.34. The company's stock had a trading volume of 283,025 shares, compared to its average volume of 272,845. The stock's 50-day moving average is $10.88 and its two-hundred day moving average is $10.54. The firm has a market capitalization of $478.11 million, a PE ratio of -4.33 and a beta of 1.19. iTeos Therapeutics has a one year low of $8.20 and a one year high of $18.24.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($1.03) by $0.18. Analysts expect that iTeos Therapeutics will post -4.76 EPS for the current fiscal year.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.